Re-Imagining Clinical Development Strategy|Suzanne Vyvoda Founder,CEO of Concordia BioStrategies|E16 скачать в хорошем качестве

Re-Imagining Clinical Development Strategy|Suzanne Vyvoda Founder,CEO of Concordia BioStrategies|E16

Episode Overview In this episode, we sit down with Suzanne Vyvoda, Founder and CEO of Concordia BioStrategies, to explore how strategic leadership, operational rigor, and collaborative execution are essential to building successful biotech companies. Suzanne shares her journey and the philosophy behind Concordia, her role as a Fractional C-Suite Leader, and why strong operational foundations must be established early—often before a clinical trial even begins. This conversation offers practical insights for emerging biotech leaders navigating the transition from discovery to the clinic, while balancing speed, quality, and long-term value creation. Key Topics Discussed Suzanne’s path to becoming a founder, CEO, and trusted strategic partner to biotech companies. How the name reflects a philosophy of alignment, collaboration, and shared purpose in clinical development. What it means to be a Fractional C-Suite leader and why this model is increasingly valuable for emerging biotechs. How fractional leadership provides senior expertise without the overhead of full-time executives. Why operational excellence must start well before clinical trials—not after problems arise. Common operational pitfalls biotech startups face as they transition into clinical development. How companies can move fast while maintaining quality, compliance, and scientific integrity. Aligning strategy, operations, and execution to avoid delays and costly missteps. Creating alignment between founders, teams, CROs, and partners. How early operational decisions influence scalability, investor confidence, and patient impact. Episode Highlights A compelling founder story rooted in collaboration and strategic clarity Clear explanation of the Fractional C-Suite model and its growing importance Practical guidance on operational readiness in early biotech Real-world insights into avoiding common clinical-stage pitfalls A thoughtful framework for balancing speed, quality, and execution